Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.

Filter

Date Title Topic
21 Sep 2018 EMA Recommends Granting Marketing Authorisation for Brigatinib Lung and other thoracic tumours - Personalised medicine - Anticancer agents & Biologic therapy
21 Sep 2018 ESMO Launches New Patient Guide in Cervical Cancer Gynaecologic malignancies
18 Sep 2018 NICE Develops Medtech Innovation Briefing on AlignRT in Breast Cancer Radiotherapy Breast cancer
17 Sep 2018 Risk of Developing Endocrinopathy Determined in Children and Young Adults after Radiotherapy for Brain Tumours Central nervous system malignancies - Cancer in Special Situations / Population
14 Sep 2018 FDA Approves Moxetumomab Pasudotox-tdfk for Hairy Cell Leukaemia Haematologic malignancies - Anticancer agents & Biologic therapy
13 Sep 2018 New US Preventive Services Task Force Recommendations for Cervical Cancer Screening Epidemiology/Etiology/Cancer Prevention
12 Sep 2018 Sixteen EU Member States Sign the Genomics Declaration Bioethics, legal and economic issues - Personalised medicine
11 Sep 2018 NICE Issues Evidence-Based Recommendations on Lenvatinib and Sorafenib for Treatment of Differentiated Thyroid Cancer Endocrine and neuroendocrine tumours - Anticancer agents & Biologic therapy
10 Sep 2018 China National Drug Administration Grants Approval to Alectinib for ALK-positive NSCLC Lung and other thoracic tumours - Anticancer agents & Biologic therapy
07 Sep 2018 NICE Issues Evidence-Based Recommendations for Lutetium (177Lu) Oxodotreotide for Treating GEP NETs Endocrine and neuroendocrine tumours
06 Sep 2018 NICE Issues Evidence Based Recommendations on Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma in Adults Haematologic malignancies - Cancer Immunology and Immunotherapy
05 Sep 2018 FDA Updates Prescribing Information for Pembrolizumab and Atezolizumab Genitourinary cancers - Cancer Immunology and Immunotherapy
04 Sep 2018 FDA Grants Regular Approval for Pembrolizumab in Combination with Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
03 Sep 2018 FDA Grants Nivolumab Accelerated Approval for Third-Line Treatment of Metastatic Small Cell Lung Cancer Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
31 Aug 2018 EMA Restricts Use of Prostate Cancer Medicine Radium-223 Dichloride Genitourinary cancers